Physician profile
Jaclyn A Smith
NPI 1235669755
$1,731.98
in general payments reported to CMS, 2019-2025
21 companies · $485 in 2025
The $485 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.06 · 2021: $19.88 · 2022: $238 · 2023: $564 · 2024: $408 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,456.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $328.47 | 2022-2025 | |
| Abbvie INC. | $262.16 | 2022-2025 | Skyrizi |
| Novartis Pharmaceuticals Corporation | $256.59 | 2022-2025 | |
| Amgen INC. | $102.74 | 2023-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $96.19 | 2023-2025 | Libtayo, Dupixent |
| Pfizer INC. | $81.96 | 2022-2025 | |
| Lilly USA, LLC | $75.75 | 2023-2024 | Taltz, Olumiant |
| Galderma Laboratories, L.P. | $72.55 | 2021-2023 | |
| Janssen Biotech, INC. | $72.18 | 2022-2024 | Tremfya |
| Incyte Corporation | $61.42 | 2023-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $60.05 | 2022-2024 | |
| Leo Pharma INC. | $45.63 | 2022-2023 | Adbry |
| Arcutis Biotherapeutics, INC. | $44.99 | 2023-2025 | Zoryve |
| Kyowa Kirin, INC. | $36.82 | 2023 | Poteligeo |
| Verrica Pharmaceuticals INC. | $24.76 | 2025 | Ycanth |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $21.54 | 2023 | Valchlor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.78 | 2023 | Spevigo |
| Kerecis Limited | $18.74 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Celgene Corporation | $18.06 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.87 | 2023 | Sotyktu |
| Merck Sharp & Dohme LLC | $14.73 | 2023 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaclyn Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.